Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts

[en] Assessing bone turnover is a key diagnostic tool in the global management of chronic kidney disease-mineral and bone disorder (CKD-MBD). Since bone biopsy is invasive and cannot be repeated in clinical practice and because bone histomorphometry is less available due to the lack of specialized laboratories, we will focus on potential biomarkers used to assess and monitor bone turnover. After briefly reviewing the pathophysiology of bone turnover in CKD and haemodialysis patients, we will focus on the strengths and limitations of the now recommended biomarkers, i.e. parathormone and bone-specific alkaline phosphatase. We will consider the clinical and also the biological aspects of the topic and also insist on the use of these biomarkers for the monitoring, and the follow-up of the turnover in haemodialysis subjects. Finally, we will discuss some of the most promising, but still not recommended, emerging biomarkers.

Disciplines :

Laboratory medicine & medical technology

Author, co-author :

DELANAYE, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie

Souberbielle, Jean-Claude

Lafage-Proust, Marie-Hélène

Jean, Guillaume

CAVALIER, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale

Language :

English

Title :

Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts

Publication date :

May 2014

Journal title :

Nephrology Dialysis Transplantation

ISSN :

0931-0509

eISSN :

1460-2385

Publisher :

Oxford University Press, Oxford, United Kingdom

Volume :

Issue :

Pages :

997-1004

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 18 July 2013

Statistics

Number of views

106 (13 by ULiège)

Number of downloads

9 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-S130
Mac Way F, Lessard M, Lafage-Proust MH. Pathophysiology of chronic kidney disease-mineral and bone disorder. Joint Bone Spine 2012; 79: 544-549
Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358-1366
Stevens LA, Djurdjev O, Cardew S et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779
Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
Bervoets AR, Spasovski GB, Behets GJ et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 2003; 41: 997-1007
Coen G, Ballanti P, Bonucci E et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 2294-2302
Monier-Faugere MC, Geng Z, Mawad H et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60: 1460-1468
Urena P, Hruby M, Ferreira A et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 506-512
Cavalier E, Delanaye P, Moranne O. Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis 2013; 61: 847-848
Ricos C, Alvarez V, Cava F et al. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 1999; 59: 491-500
Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011; 26: 1368-1376
Kovesdy CP, Quarles LD. Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrol Dial Transplant 2013. [Epub ahead of print]
Pelletier S, Dubourg L, Carlier MC et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013; 8: 819-823
Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121
Nussbaum SR, Zahradnik RJ, Lavigne JR et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33: 1364-1367
Slatopolsky E, Finch J, Clay P et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58: 753-761
Souberbielle JC, Boutten A, Carlier MC et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006; 70: 345-350
Gao P, Scheibel S, D'Amour P et al. Development of a novel immunora-diometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001; 16: 605-614
Coen G, Bonucci E, Ballanti P et al. PTH 1-84 and PTH '7-84' in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002; 40: 348-354
Lehmann G, Stein G, Huller M et al. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histo-morphometry. Kidney Int 2005; 68: 1206-1214
Salusky IB, Goodman WG, Kuizon BD et al. Similar predictive value of bone turnover using first-and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 2003; 63: 1801-1808
Sawaya BP, Butros R, Naqvi S et al. Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Kidney Int 2003; 64: 737-742
Cosman F, Morgan DC, Nieves JW et al. Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res 1997; 12: 958-966
Melamed ML, Eustace JA, Plantinga LC et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant 2008; 23: 1650-1658
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-201
Barreto FC, Barreto DV, Moyses RM et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777
Cavalier E, Delanaye P, Vranken L et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2012; 27: 1950-1956
Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008; 12: 514-525
Qunibi W, Kalantar-Zadeh K. Target levels for serum phosphorus and parathyroid hormone. Semin Dial 2011; 24:29-33
Gardham C, Stevens PE, Delaney MP et al. Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol 2010; 5: 1261-1267
Harris H. The human alkaline phosphatases: what we know and what we don't know. Clin Chim Acta 1990; 186: 133-150
Fletcher S, Jones RG, Rayner HC et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997; 75: 412-419
Delanaye P, Dubois BE, Jouret F et al. Parathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients: is it so simple? Clin Chim Acta 2013; 417: 35-38
Moore C, Yee J, Malluche H et al. Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1484-1493
Jean G, Souberbielle JC, Granjon S et al. Bone biomarkers in haemodialy-sis patients: Bone alkaline phosphatase or (3-Crosslaps?. Nephrol Ther 2013; 9: 154-159
Jean G, Souberbielle JC, Zaoui E et al. Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease. Clin Biochem 2012; 45: 436-439
Coen G, Ballanti P, Balducci A et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002; 17: 233-238
Hutchison AJ, Whitehouse RW, Boulton HF et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993; 44: 1071-1077
Cavalier E, Delanaye P, Collette J et al. Evaluation of different bone markers in hemodialyzed patients. Clin Chim Acta 2006; 371: 107-111
Jarava C, Armas JR, Salgueira M et al. Bone alkaline phosphatase isoenzyme in renal osteodystrophy. Nephrol Dial Transplant 1996; 11(Suppl. 3): 43-46
Couttenye MM, D'Haese PC, Van Hoof VO et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1065-1072
Lehmann G, Ott U, Kaemmerer D et al. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3-5. Clin Nephrol 2008; 70: 296-305
Iimori S, Mori Y, Akita W et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-A single-center cohort study. Nephrol Dial Transplant 2012; 27: 345-351
Beddhu S, Ma X, Baird B et al. Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1805-1810
Regidor DL, Kovesdy CP, Mehrotra R et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19: 2193-2203
Blayney MJ, Pisoni RL, Bragg-Gresham JL et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitaliza-tion and death. Kidney Int 2008; 74: 655-663
Kovesdy CP, Ureche V, Lu JL et al. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant 2010; 25: 3003-3011
Kobayashi I, Shidara K, Okuno S et al. Higher serum bone alkaline phos-phatase as a predictor of mortality in male hemodialysis patients. Life Sci 2012; 90: 212-218
Drechsler C, Verduijn M, Pilz S et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 2011; 6: 1752-1759
Cavalier E, Rozet E, Carlisi A et al. Analytical validation of serum bone alkaline phosphatase (BAP OSTASE) on Liaison. Clin Chem Lab Med 2010; 48: 67-72
Cavalier E, Delanaye P, Carlisi A et al. Stability of intact parathyroid hormone in samples from hemodialysis patients. Kidney Int 2007; 72: 370-372
Sardiwal S, Gardham C, Coleman AE et al. Bone-specific alkaline phos-phatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int 2012; 82: 100-105
Garrett G, Sardiwal S, Lamb EJ et al. PTH-A Particularly Tricky Hormone: Why Measure It at All in Kidney Patients?. Clin J Am Soc Nephrol 2012; 8: 299-312
Sanchez C, Lopez-Barea F, Sanchez-Cabezudo J et al. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 2004; 19: 1587-1593
Jean G, Chazot C, Charra B. 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin Nephrol 2007; 68: 63-64
Vasikaran S, Eastell R, Bruyere O et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011; 22: 391-420
Nakasato YR, Janckila AJ, Halleen JM et al. Clinical significance of immu-noassays for type-5 tartrate-resistant acid phosphatase. Clin Chem 1999; 45: 2150-2157
Halleen JM, Alatalo SL, Suominen H et al. Tartrate-resistant acid phos-phatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15: 1337-1345
Shidara K, Inaba M, Okuno S et al. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 2008; 82: 278-287
Chu P, Chao TY, Lin YF et al. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 2003; 41: 1052-1059
Koivula MK, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clin Biochem 2012; 45: 920-927
Melkko J, Hellevik T, Risteli L et al. Clearance of NH2-terminal propep-tides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 1994; 179: 405-412
Ueda M, Inaba M, Okuno S et al. Clinical usefulness of the serum N-ter-minal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 2002; 40: 802-809
Kleerekoper M. Biochemical markers of bone remodeling. Am J Med Sci 1996; 312: 270-277
Garnero P, Hausherr E, Chapuy MC et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11: 1531-1538
Qvist P, Christgau S, Pedersen BJ et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002; 31: 57-61
Reichel H, Roth HJ, Schmidt-Gayk H. Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone re-sorption in chronic hemodialysis patients. Nephron Clin Pract 2004; 98: c112-c118
Okabe R, Nakatsuka K, Inaba M et al. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides. Clin Chem 2001; 47: 1410-1414
Malyszko J, Wolczynski S, Zbroch E et al. Brzosko S, Malyszko J, Mysli-wiec M. Serum crosslaps correlations with serum ICTP and urine DPD in hemodialyzed and peritoneally dialyzed patients. Nephron 2001; 87: 283-285
Negri AL, Quiroga MA, Bravo M et al. Serum crosslaps as bone resorption marker in peritoneal dialysis. Perit Dial Int 2002; 22: 628-630
Graf S, Bohner J, Hertel A. Evaluation of Beta-CrossLaps in haemodialysis patients. Nephrol Dial Transplant 2013; 18(Suppl. 4): 407